R5 to X4 Switch of the Predominant HIV-1 Population in Cellular Reservoirs During Effective Highly Active Antiretroviral Therapy
暂无分享,去创建一个
Christophe Pasquier | Michelle Cazabat | Jacques Izopet | P. Massip | C. Pasquier | K. Sandres‐Saune | J. Izopet | P. Delobel | B. Marchou | M. Cazabat | Pierre Delobel | Patrice Massip | Bruno Marchou | Karine Sandres-Sauné | K. Sandres-Sauné
[1] Robert F. Siliciano,et al. Characterization of Chemokine Receptor Utilization of Viruses in the Latent Reservoir for Human Immunodeficiency Virus Type 1 , 2000, Journal of Virology.
[2] K. Anastos,et al. Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy. , 2001, The Journal of clinical investigation.
[3] R. Paranjape,et al. Absence of coreceptor switch with disease progression in human immunodeficiency virus infections in India. , 2000, Virology.
[4] J. Sleasman,et al. Envelope V3 amino acid sequence predicts HIV-1 phenotype (co-receptor usage and tropism for macrophages). , 2000, AIDS.
[5] J. Margolick,et al. Improved Coreceptor Usage Prediction and GenotypicMonitoring of R5-to-X4 Transition by Motif Analysis of HumanImmunodeficiency Virus Type 1 env V3 LoopSequences , 2003, Journal of Virology.
[6] Mario Roederer,et al. T-Cell Subsets That Harbor Human Immunodeficiency Virus (HIV) In Vivo: Implications for HIV Pathogenesis , 2004, Journal of Virology.
[7] Anthony S. Fauci,et al. Both Memory and CD45RA+/CD62L+ Naive CD4+ T Cells Are Infected in Human Immunodeficiency Virus Type 1-Infected Individuals , 1999, Journal of Virology.
[8] C. A. Macken,et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. , 1999, The New England journal of medicine.
[9] J Leibowitch,et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. , 1997, Science.
[10] David Camerini,et al. Expression and Function of Chemokine Receptors on Human Thymocytes: Implications for Infection by Human Immunodeficiency Virus Type 1 , 2001, Journal of Virology.
[11] A. Lafeuillade,et al. Residual human immunodeficiency virus type 1 RNA in lymphoid tissue of patients with sustained plasma RNA of <200 copies/mL. , 1998, The Journal of infectious diseases.
[12] P. Vernazza,et al. Characterization of V3 Sequence Heterogeneity in Subtype C Human Immunodeficiency Virus Type 1 Isolates from Malawi: Underrepresentation of X4 Variants , 1999, Journal of Virology.
[13] D. Richman,et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.
[14] R. Corrêa,et al. Viral phenotype affects the thymic production of new T cells in HIV-1-infected children , 2001, AIDS.
[15] P. Massip,et al. Evolution of total and integrated HIV-1 DNA and change in DNA sequences in patients with sustained plasma virus suppression. , 2002, Virology.
[16] H. Schuitemaker,et al. Both R5 and X4 Human Immunodeficiency Virus Type 1 Variants Persist during Prolonged Therapy with Five Antiretroviral Drugs , 2002, Journal of Virology.
[17] J. Lisziewicz,et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.
[18] Jaap Goudsmit,et al. N-Linked Glycosylation of the HIV Type-1 gp120 Envelope Glycoprotein as a Major Determinant of CCR5 and CXCR4 Coreceptor Utilization* , 2001, The Journal of Biological Chemistry.
[19] J. McNamara,et al. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team. , 1998, The Journal of pediatrics.
[20] James I Mullins,et al. Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy , 2004, AIDS.
[21] J. Metcalf,et al. HIV-1 replication in patients with undetectable plasma virus receiving HAART , 1999, The Lancet.
[22] G. d’Ettorre,et al. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy , 2003, Journal of medical virology.
[23] H. Schuitemaker,et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population , 1992, Journal of virology.
[24] D. Richman,et al. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. , 1994, The Journal of infectious diseases.
[25] F. Barré-Sinoussi,et al. Positive Regulation of CXCR4 Expression and Signaling by Interleukin-7 in CD4+ Mature Thymocytes Correlates with Their Capacity To Favor Human Immunodeficiency X4 Virus Replication , 2003, Journal of Virology.
[26] J. Goudsmit,et al. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution , 1992, Journal of virology.
[27] H. Schuitemaker,et al. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule , 1992, Journal of virology.
[28] M. Sim,et al. Recovery of replication-competent virus from CD4 T cell reservoirs and change in coreceptor use in human immunodeficiency virus type 1-infected children responding to highly active antiretroviral therapy. , 2000, The Journal of infectious diseases.
[29] B. Haynes,et al. Immune reconstitution in patients with HIV infection. , 2002, Annual review of medicine.
[30] M. Rey-Cuillé,et al. N-linked glycosylation in the V3 region of HIV type 1 surface antigen modulates coreceptor usage in viral infection. , 2001, AIDS research and human retroviruses.
[31] J. Margolick,et al. Consistent Viral Evolutionary Changes Associated with the Progression of Human Immunodeficiency Virus Type 1 Infection , 1999, Journal of Virology.
[32] C. Mackay,et al. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[33] Rami Kantor,et al. High Frequency of Syncytium-Inducing and CXCR4-Tropic Viruses among Human Immunodeficiency Virus Type 1 Subtype C-Infected Patients Receiving Antiretroviral Treatment , 2003, Journal of Virology.
[34] I. Keet,et al. Prognostic Value of HIV-1 Syncytium-Inducing Phenotype for Rate of CD4+ Cell Depletion and Progression to AIDS , 1993, Annals of Internal Medicine.
[35] R Brookmeyer,et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.
[36] B. Clotet,et al. Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia. , 1999, Virology.
[37] J Witek,et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. , 1999, JAMA.
[38] Huisman,et al. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex , 1988, Journal of virology.
[39] E. Nicastri,et al. HIV phenotype switching during antiretroviral therapy: emergence of saquinavir‐resistant strains with less cytopathogenicity , 1997, AIDS.
[40] B. Korber,et al. A new classification for HIV-1 , 1998, Nature.
[41] Antonio Lanzavecchia,et al. Central memory and effector memory T cell subsets: function, generation, and maintenance. , 2004, Annual review of immunology.
[42] R. Lal,et al. CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: delineation of consensus motif in the V3 domain that predicts CCR-5 usage. , 1998, Virology.
[43] J. Barretina,et al. Interleukin-7 in Plasma Correlates with CD4 T-Cell Depletion and May Be Associated with Emergence of Syncytium-Inducing Variants in Human Immunodeficiency Virus Type 1-Positive Individuals , 2001, Journal of Virology.
[44] C. Farber,et al. In vivo inhibition of syncytium-inducing variants of HIV in patients treated with didanosine. , 1995, AIDS.
[45] Alan S. Perelson,et al. Evolution of Envelope Sequences of Human Immunodeficiency Virus Type 1 in Cellular Reservoirs in the Setting of Potent Antiviral Therapy , 1999, Journal of Virology.
[46] V. Trouplin,et al. Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations , 2003, AIDS.
[47] H. Schuitemaker,et al. In vivo HIV-1 infection of CD45RA(+)CD4(+) T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4(+) T cell decline. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[48] J. Farber,et al. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.
[49] L. Ratner,et al. Analysis of the Critical Domain in the V3 Loop of Human Immunodeficiency Virus Type 1 gp120 Involved in CCR5 Utilization , 1999, Journal of Virology.
[50] Alan S. Perelson,et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy , 2000, Nature Medicine.